Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Onchilles Pharma logo — Developing drug candidates that have the potential to be bro...

Onchilles Pharma

Developing drug candidates that have the potential to be broadly effective against a wide range of cancers.

Founded 2017 United States San Diego, United States 10 employees Series B Total: $39.15M Biopharma, Biotechnology +1

General Information

Company Name Onchilles Pharma
Founded Year 2017
Location United States San Diego, United States +1
Founders / Decision Makers
Team member
Employees 10
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series B
Social

Get notified when Onchilles Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Onchilles Pharma

Onchilles Pharma, founded in 2017, is a private biotech firm headquartered in the United States at the Alexandria GradLabs in San Diego. Specializing in the Biopharma, Biotechnology, and Pharmaceutical industries, the company is focused on developing drug candidates with the slogan: "Developing drug candidates that have the potential to be broadly effective against a wide range of cancers."

The company emerged from groundbreaking research that uncovered a novel neutrophil pathway capable of selectively and comprehensively killing cancer cells. This pioneering research supports Onchilles Pharma’s pipeline of first-in-class drugs exhibiting broad efficacy against various cancers.

On 01 November 2025, Onchilles secured a $25.00M Series B investment, demonstrating strong investor confidence. Key investors included LYZZ CAPITAL, InVivium Capital, Lincoln Park Capital Fund, and Kennedy Lewis Investment Management LLC.

Taxonomy: cancer therapeutics, biotech innovation, first-in-class biologics, neutrophil pathway research, oncology drug development, selective cancer cell targeting, non-toxic cancer treatment, San Diego biotech, Alexandria GradLabs, private biotech company, broad cancer effectiveness, biologics therapies, cancer cell cytotoxicity, novel pharmaceutical pathways, drug candidate pipeline

Services & Products

Drug discovery and development
Cancer-selective killing therapies
Clinical trial advancement

Target Customers

Healthcare providers Cancer treatment centers Oncologists Pharmaceutical partners

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 4
Investor Investor Investor Investor
01 Nov 2025
Series A •••••• 2
Investor Investor
01 Jun 2021
Series A •••••• 1
Investor
01 Jul 2020
Grant •••••• 1
Investor
01 Dec 2017
Spinout •••••• 1
Investor
01 Jan 2017

Onchilles Pharma Alternatives & Competitors

View All Alternatives
Onchilles Pharma vs
Cancer Research Horizons
Cancer Research Horizons United Kingdom

We are Cancer Research UK's innovation arm, translating discovery into breakthrough treatments.

147 employees
Biotechnology, Health Care
Onchilles Pharma vs
Biond Biologics Ltd
Biond Biologics Ltd Israel

Biond - Innovative immunotherapies and a pioneering intracellular delivery for biologics for the tre...

Series C
43 employees
Biotechnology, Health Care
Onchilles Pharma vs
Bright Peak Therapeutics
Bright Peak Therapeutics Switzerland

Better Biologics Through Chemistry

Series C
56 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Onchilles Pharma

Developing drug candidates that have the potential to be broadly effective against a wide range of cancers.
Onchilles Pharma was founded in 2017.
Onchilles Pharma is headquartered in San Diego, United States.
Onchilles Pharma operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Onchilles Pharma has approximately 10 employees.
Onchilles Pharma has completed 5 funding rounds, raising a total of $39.15M. The latest funding stage is Series B.
Onchilles Pharma offers: Drug discovery and development, Cancer-selective killing therapies, Clinical trial advancement.
Top alternatives and competitors to Onchilles Pharma include Cancer Research Horizons, Biond Biologics Ltd, Bright Peak Therapeutics, CTMC - a joint venture between Resilience + MD Anderson Cancer Center, SCG Cell Therapy. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Onchilles Pharma and Cancer Research Horizons are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Onchilles Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy